KRAS mutations are predominant in many cancers, including PDAC, NSCLC, and CRC, and alongside the FDA-approved KRAS G12C inhibitor, sotorasib, acquired clinical resistance. This evidence concerns the gene KRAS and colorectal carcinoma.